Volatile Fatty Acids

Subscribe to Selected New Research on Volatile Fatty Acids

368 relevant articles (14 outcomes, 50 trials/studies) found for this Bio-Agent

Description: Short-chain fatty acids of up to six carbon atoms in length. They are the major end products of microbial fermentation in the ruminant digestive tract and have also been implicated in the causation of neurological diseases in humans.

Also Known As:

Fatty Acids, Volatile; Fatty Acids, Short Chain; Short-Chain Fatty Acids; Fatty Acids, Short-Chain

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13939

Fatty Acids: 4922

Volatile Fatty Acids: 368

Experts

1.	Fal'ko, E V: 1 article (08/2008)
2.	Khyshiktuev, B S: 1 article (08/2008)
3.	Van Immerseel, Filip: 1 article (08/2008)
4.	Ducatelle, Richard: 1 article (08/2008)
5.	Van Deun, Kim: 1 article (08/2008)
6.	Karavaeva, T M: 1 article (08/2008)
7.	Haesebrouck, Freddy: 1 article (08/2008)
8.	Pasmans, Frank: 1 article (08/2008)
9.	Johansson Hagslätt, Marie-Louise: 1 article (09/2007)
10.	Berggren, Anna: 1 article (09/2007)

Related Diseases

1.	Ulcerative Colitis 11/01/1996 - "This study showed trends towards a beneficial effect of topical short-chain fatty acids in active ulcerative colitis, but more patients are needed to demonstrate this effect with sufficient statistical power." 01/01/2005 - "[Role of short-chain fatty acids in the pathogenesis and therapy of ulcerative colitis]" 01/01/1998 - "Short-chain fatty acids in ulcerative colitis." 04/01/1996 - "OBJECTIVES: To determine the efficacy and safety of short chain fatty acids (SCFA) in the treatment of refractory distal ulcerative colitis (UC). " 11/01/1995 - "Short chain fatty acids (SCFAs) are potentially valuable as a topical therapy for distal ulcerative colitis. " Order ALL the reference details at left...
2.	Colitis 09/01/2000 - "In this study, we investigated the roles of the intestinal microflora and short chain fatty acids (SCFAs) following administration of GBF in DSS-induced rat colitis. " 11/01/1995 - "The aim of the study was to evaluate the effectiveness of short chain fatty acids on microbial flora of patients with diversion colitis and to compare this flora to the microbial flora of controls. " 02/01/1991 - "To test whether irrigation of the inflamed mucosa with short-chain fatty acids is useful, we conducted a six-week preliminary trial in 12 patients with distal colitis. " 05/01/2002 - "Short-chain fatty acids (SCFAs), which remain poorly documented in experimental colitis, were also investigated. " 10/01/2001 - "Diversion procto-colitis: response to treatment with short-chain fatty acids." Order ALL the reference details at left...
3.	Infection 01/01/2007 - "One of modern and highly effective methods of diagnostics and differential diagnostics of infected pancreonecrosis is chromatographic technique, which allows for identification of anaerobic non-clostridial infection in the foci of pancreatic destruction by the presence of volatile fatty acids, the specific end products of anaerobic bacterial metabolism. " 03/01/2006 - "japonicum infection in the hamster was the inhibition of manufacture or utilization of short-chain fatty acids, when compared to a S. " 01/01/2004 - "Microencapsulated short-chain fatty acids in feed modify colonization and invasion early after infection with Salmonella enteritidis in young chickens." 01/01/2003 - "It is actually in case of infections provoked by opportunistically pathogenic microorganisms that the key task consists not in the elimination of bacteria but in the normalization of the host-microbe relations; the possibility to decipher the conduct of microbes through understanding the molecules' signals will provide a clue to comprehending and regulating such most important etiological-and-pathogenetic mechanisms as adhesions, pathological colonization, metabolic activity, bacterial super-growth etc. The confirmed ability of volatile fatty acids (end-products of anaerobic bacteria) to suppress the inflammatory reaction of macrophages urges further search for microbe metabolites with the anti-inflammatory activity. " 11/01/2000 - "Significance of fecal volatile fatty acids in shedding of Escherichia coli O157 from calves: experimental infection and preliminary use of a probiotic product." Order ALL the reference details at left...
4.	Diarrhea 04/01/1994 - " Studies with their corresponding findings have continued since then, with current efforts focused upon developing a treatment for diarrhea using the role of short chain fatty acids in acute watery diarrhea." 09/01/2007 - "Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea." 03/01/1993 - "In the intestinal flora of patients with diarrhea, a close correlation exists between a decrease in numbers of anaerobes and a reduction in levels of short-chain fatty acids. " 12/01/1991 - "Compared with controls, the colonic fermentation was markedly impaired in patients with antibiotic-associated diarrhea reflected by both very low concentrations (22.1 vs. 59.5 mmol/L; P less than 0.01) and production rates of short-chain fatty acids. " 12/01/1991 - "Colonic fermentation to short-chain fatty acids is decreased in antibiotic-associated diarrhea." Order ALL the reference details at left...
5.	Atrophy 09/01/1989 - "Mucosal atrophy induced by total parenteral nutrition in rats was prevented by the intravenous administration of short-chain fatty acids." 02/01/1999 - "The aim of this study was to determine the relationship between gut mucosal atrophy, bacterial translocation, and catheter sepsis in rats receiving TPN alone or supplemented with intravenous short chain fatty acids (SCFA) or glutamine. " 03/01/1997 - "Total parenteral nutrition (TPN) induces intestinal atrophy that is prevented by the systemic administration of short-chain fatty acids (SCFAs) as measured by morphological indices (i.e., mucosal weight and mucosal DNA, RNA, and protein concentration). " 01/01/1997 - "With the release of the short-chain fatty acids butyric or propionic acid during the hydrolysis of a structured triglyceride containing butyric acid (C4-L-C4-TG) or the beta-oxidation of nonanoic acid from trinonanoin (C9TG), respectively, the infusion of these two triglycerides was supposed to reveal positive effects against the TPN-induced atrophy of the intestine. " 12/01/2001 - "Selected important clinical learning points include the following: (1) glucose absorption mediated by SGLT1 is controlled by mRNA abundance, as well as by posttranscriptional processes including protein trafficking; (2) inducers of cytochrome P-450 decrease glucose and fructose absorption and increase glucose consumption in the intestine; (3) the regulated release of nutrients from the stomach into the upper intestine ensures that the modest intestinal transport reserve capacity is not exceeded; (4) hepatocyte growth factor and short-chain fatty acids may enhance intestinal adaptation and prevent the atrophy seen when total parenteral nutrition is infused; (5) inhibitors of pancreatic lipase and phospholipase H2 may be useful clinically to reduce absorption as part of a treatment program for obesity and hyperlipidemia; (6) several membrane-bound and cytosolic proteins have been identified in the enterocyte as well as in the hepatocyte and may be the target for the future therapeutic manipulation of bile acid metabolism and control of hyperlipidemia; (7) suspect bile acid malabsorption in the patient with otherwise unexplained chronic diarrhea; (8) a proportion of lipid absorption is protein-mediated, and this opens the way to targeting these proteins and thereby therapeutically modifying lipid absorption; (9) a high protein diet may be useful to increase the intestinal absorption of drugs transported by the H+/dipeptide cotransporter; (10) a metal transporter DCT1 has been identified, and this may open the way to a better understanding of disorders of, for example, iron and zinc metabolism; (11) the nutrient transporters such as SGLT1 are responsible for a portion of the intestinal absorption of water; (12) the influence of nitric oxide on intestinal water absorption and secretion depends on its concentration; (13) a trial of bile acid-sequestering agent may prove useful in the treatment of the patient who experiences diarrhea while taking an enteral diet; (14) a proteolytic extract from pineapple stems may prove to be useful to treat diarrhea, although the mechanism of this effect remains to be established; and (15) the antisecretory effect of the new peptide, sorbin, needs to be tested in a clinical situation on patients with diarrhea. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Butyrates (Butyrate)
2.	Glucose (Dextrose)
3.	Glutamine (L-Glutamine)
4.	Ammonia
5.	Phenobarbital (Luminal)
6.	Proteins (Proteins, Gene)
7.	Lipase (Acid Lipase)
8.	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
9.	Zinc
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Enema (Enemas)
2.	Total Parenteral Nutrition
3.	Oral Administration
4.	Ileostomy
5.	Enteral Nutrition (Feeding, Tube)

Best Treatments:
Research Summary Report
on Ulcerative Colitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 827 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>